Ustekinumab versus Vedolizumab for Moderate to Severe Crohn's Disease

被引：1
|
作者：
Singh, Amandeep [1 ]
Khan, Freeha [1 ]
Lopez, Rocio [1 ]
Shen, Bo [1 ]
机构：
[1] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2017年 / 112卷
关键词：
D O I：
10.14309/00000434-201710001-00713
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
713
引用
收藏
页码：S393 / S394
页数：2
相关论文
共 50 条
  • [1] Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease
    Peyrin-Biroulet, Laurent
    Chapman, J. Casey
    Colombel, Jean-Frederic
    Caprioli, Flavio
    D'Haens, Geert
    Ferrante, Marc
    Schreiber, Stefan
    Atreya, Raja
    Danese, Silvio
    Lindsay, James O.
    Bossuyt, Peter
    Siegmund, Britta
    Irving, Peter M.
    Panaccione, Remo
    Cao, Qian
    Neimark, Ezequiel
    Wallace, Kori
    Anschutz, Toni
    Kligys, Kristina
    Duan, W. Rachel
    Pivorunas, Valerie
    Huang, Xiu
    Berg, Sofie
    Shu, Lei
    Dubinsky, Marla
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (03): : 213 - 223
  • [2] Ustekinumab: A Review in Moderate to Severe Crohn’s Disease
    Yvette N. Lamb
    Sean T. Duggan
    [J]. Drugs, 2017, 77 : 1105 - 1114
  • [3] Ustekinumab: A Review in Moderate to Severe Crohn's Disease
    Lamb, Yvette N.
    Duggan, Sean T.
    [J]. DRUGS, 2017, 77 (10) : 1105 - 1114
  • [4] Ustekinumab for Moderate to Severe Crohn's Disease and Its Extraintestinal Manifestations
    Singh, Amandeep
    Khan, Freeha
    Lopez, Rocio
    Shen, Bo
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S1482 - S1482
  • [5] REAL LIFE EFFECTIVENESS OF USTEKINUMAB FOR MODERATE TO SEVERE CROHN'S DISEASE
    Miranda, A.
    Cuomo, A.
    Camera, S.
    Ciacci, C.
    De Filippo, F. R.
    D'Onofrio, V.
    Melina, R.
    Manguso, F.
    Bennato, R.
    Cuomo, R.
    Mucherino, C.
    Facchiano, A.
    Rigler, G.
    Sgambato, D.
    Ciamarra, P.
    Romano, M.
    [J]. DIGESTIVE AND LIVER DISEASE, 2020, 52 : S38 - S38
  • [6] Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
    Amanda Hansson-Hedblom
    Chrissy Almond
    Fredrik Borgström
    Indeg Sly
    Dana Enkusson
    Anders Troelsgaard Buchholt
    Linda Karlsson
    [J]. Cost Effectiveness and Resource Allocation, 16
  • [7] Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden
    Hansson-Hedblom, Amanda
    Almond, Chrissy
    Borgstrom, Fredrik
    Sly, Indeg
    Enkusson, Dana
    Buchholt, Anders Troelsgaard
    Karlsson, Linda
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
  • [8] Efficacy of Combination Vedolizumab and Ustekinumab for Refractory Crohn's Disease
    Huff-Hardy, Kayci
    Bedair, Mai
    Vazquez, Rebecca
    Burstein, Ezra
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 (10) : E49 - E49
  • [9] FISTULA HEALING IN PATIENTS WITH CROHN'S DISEASE ON USTEKINUMAB AND VEDOLIZUMAB
    Newman, Kira L.
    Johnson, Laura A.
    Stidham, Ryan
    Higgins, Peter D.
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S821 - S822
  • [10] EFFICACY AND SAFETY OF USTEKINUMAB AND VEDOLIZUMAB FOR CROHN'S DISEASE OF THE POUCH
    Park, Sunhee
    Keyashian, Kian
    Ho, Andrew
    Limsui, David
    Frost, Spencer
    Vazquez-Reyes, Raul
    Ebriani, Joseph
    Yang, Eleanor
    Parekh, Nimisha K.
    Sauk, Jenny S.
    Limketkai, Berkeley N.
    [J]. GASTROENTEROLOGY, 2022, 162 (07) : S146 - S146
12345